Developed at the University of Queensland’s drug discovery group, QED-203 targets the TRPV6 calcium ion channel, which is frequently linked to the aggressive progression of prostate cancer. By focusing on this mechanism, researchers hope to offer a new path for patients whose conditions have become resistant to standard therapeutic options, a group that currently faces limited clinical choices.

Under the terms of the agreement, the Los Angeles-based Ellison Medical Institute will take the lead on preclinical development and safety activities. This effort builds upon more than 15 years of academic research led by Professor Greg Monteith. The project has already secured support from several funding bodies, including the Medical Research Future Fund and the Critical Path Institute’s Translational Therapeutics Accelerator.

Dr. David Agus, founding CEO of the Ellison Medical Institute, noted that the organization’s integrated approach to oncology and drug development is designed to shorten the gap between laboratory discovery and patient care. UniQuest, which maintains a track record of commercializing university intellectual property, views this collaboration as a validation of its model for bridging academic science with specialized development partners. The transition to clinical evaluation marks a significant move toward addressing the urgent unmet needs of patients dealing with therapy-resistant disease.